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Abstract  16 
The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides 17 
results in ~4 hours. The  relationship between MBL and time-to-positivity (TTP) has not been 18 
thoroughly studied and predictive models do not exist. We aimed to develop a model for 19 
MBL and identify the MBL-TTP relationship in patients. The model was developed on data 20 
from 105 tuberculosis patients from Malawi, Mozambique and Tanzania with joint MBL and 21 
TTP observations quantified from patient sputum collected for 12 weeks. MBL was quantified 22 
using polymerase chain reaction (PCR) of mycobacterial RNA and TTP using the 23 
Mycobacterial Growth Indicator Tube (MGIT) 960 system. Treatment consisted of isoniazid, 24 
pyrazinamide and ethambutol in standard doses together with rifampicin 10 or 35 mg/kg. The 25 
developed MBL-TTP model included several linked sub-models; a component describing 26 
decline of bacterial load in sputum, another component describing growth in liquid culture 27 
and a hazard model translating bacterial growth into a TTP signal. Additional components for 28 
contaminated and negative TTP samples were included. Visual predictive checks performed 29 
using the developed model gave good description of the observed data. The model predicted 30 
greater total sample loss for TTP than MBL due to contamination and negative samples. The 31 
model detected an increase in bacterial killing for 35 versus 10 mg/kg rifampicin (p=0.002). 32 
In conclusion, a combined model for MBL and TTP was developed that described the MBL-33 
TTP relationship. The full MBL-TTP model or each sub-model used separately. Secondly, the 34 
model can be used to predict biomarker response for MBL given TTP data or vice versa in 35 
historical or future trials.   36 
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Introduction 37 
The tuberculosis (TB) burden in patients is usually quantified by culture on solid medium or 38 
in liquid culture such as the Mycobacterial Growth Indicator Tube (MGIT) (1). In the 39 
diagnostic phase, the TB burden quantification gives information on disease severity and 40 
when collected during treatment, it gives information on treatment response. Quantification 41 
has usually been done using colony forming units (CFU) on solid media (2) or time-to-42 
positivity (TTP) in liquid culture using MGIT system (1). 43 
MGIT TTP has advantages over CFU counts on solid media by being less labour-intensive 44 
and more sensitive (3) but like CFU, TTP is hampered by a high degree of sample loss due to 45 
contamination and the long time taken before results are available (5-42 days) (4). This delay 46 
has a particular impact when quantitative methods are used in patient care where individual 47 
treatment adjustment decisions based on bacterial response should ideally be quick. Time-to-48 
positivity is a time-to-event variable representing an indirect measurement of the bacterial 49 
load (high CFU gives short TTP).  50 
The molecular bacterial load (MBL) assay is a new TB biomarker which is fast (~4 hours) (4) 51 
and has limited risk of contamination (5). This is because MBL is a non-culture-based real-52 
time polymerase chain reaction (PCR) method relying on Reverse-Transcription quantitative 53 
PCR (RT-qPCR) of16S rRNA to quantify bacterial load (6). Viable TB cells contain 16S 54 
rRNA which makes MBL a continuous measurement of bacterial load. MBL can be used to 55 
predict bacterial load. 56 
MBL has weak to moderate correlation with TTP in clinical trials with reported correlations 57 
of -0.5 (4) and -0.8 (7) using Spearman rank correlation. The weak correlation is not 58 
surprising since these biomarkers are different: MBL being a direct, continuous variable and 59 
TTP being an indirect, time-to-event variable. Non-linear mixed effects models have been 60 
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applied separately to MBL- (5) and TTP- (8–10) datasets separately but a combined MBL-61 
TTP model has not been presented previously. The current TTP only models do not consider 62 
contaminated samples which are a common occurrence in culture-based detection of TB. 63 
Identifying the link between MBL and TTP could contribute to the understanding of the 64 
difference in how these biomarkers quantify bacterial burden. A combined MBL-TTP model 65 
could also be used to predict one biomarker response given information about the other 66 
biomarker providing additional insights from historical trials. Given that, in some studies 67 
contamination is common especially later in treatment, including a component for 68 
contaminated TTP samples is warranted. 69 
The objectives of this study were to develop a model for MBL and identify the relationship 70 
between MBL and TTP in pulmonary TB patients by constructing a joint MBL-TTP model.   71 
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Methods 72 
Patient data 73 
The model was developed on joint MBL and TTP observations collected repeatedly over the 74 
first 12 weeks of treatment in TB patients from an underlying study whose design and original 75 
findings are reported in detail in the relevant reference (11). Briefly, the dataset comprised of 76 
data from three clinical sites in Malawi, Mozambique and Tanzania with a total sample size of 77 
105 patients (20, 53 and 32 patients from Malawi, Mozambique and Tanzania, respectively). 78 
For the current analysis, only patients with drug-susceptible TB were included. The Tanzania 79 
data were a subset of the MAMS-TB trial that has been described in detail elsewhere (12). All 80 
patients received rifampicin and isoniazid throughout the whole study. Rifampicin was given 81 
as 10 mg/kg in 93 patients and 35 mg/kg in 12 of the patients from MAMS-TB (12). Isoniazid 82 
was given in standard dosage (5 mg/kg). Ethambutol and pyrazinamide were given in 83 
standard dosage (15-20 and 20-30 mg/kg, respectively) for the first eight weeks. Sputum was 84 
collected at baseline and at weeks 2, 4, 8 and 12 at all three sites. Sputum sampling was done 85 
either by spot sampling where sputum was collected during the on-going visit or by early 86 
morning samples where sputum was collected over-night. Pooled spot and early morning 87 
sputum was used to determine MBL and TTP for Malawi and Mozambique. For Tanzania, 88 
MBL was quantified on spot and TTP on early morning sputum. The procedure for MBL 89 
quantification was identical between sites as described previously (7). Time-to-positivity was 90 
determined using MGIT 960 (Becton-Dickinson, Sparks, MD). The TTP was tested for 91 
contamination for the Mozambique and Tanzania sites but not for Malawi. For the current 92 
analysis, samples with MBL below 100 CFU/mL were considered negative (i.e. the lower 93 
limit of quantification [LLOQ]=100 CFU/mL) (5) and TTP above 42 days were considered 94 
negative. 95 
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 96 
Modelling strategy overview 97 
The main goal with the model development was to develop a final model that described the 98 
relationship between MBL and TTP data. However, the model development was divided into 99 
first developing a MBL only model, after which TTP data was included in the modelling to 100 
develop a final, joint MBL-TTP model.  101 
For the continuous MBL biomarker directly reflecting bacterial load, we considered analysing 102 
this biomarker using models able to describe declining bacterial density in sputum, such as a 103 
bi-exponential function as applied previously to MBL data (5). The model for bacterial load 104 
was termed the sputum sub-model. 105 
The TTP data was analysed in a different fashion (8) considering it is an indirect measurement 106 
of bacterial load reflecting time-to-event data. For TTP, the experimental procedure is first to 107 
inoculate bacteria in sputum in a liquid culture where growth takes place. This was described 108 
in our approach by linking the sputum model which describes changes in bacterial load in 109 
sputum to a mycobacterial growth sub-model. The growth in liquid culture leads to carbon 110 
dioxide production and as the carbon dioxide reaches a certain level, a positive signalling 111 
event is recorded. Thus, a high degree of growth is expected to yield a high probability of 112 
achieving a short TTP and this was handled in our approach by linking the growth to the 113 
probability of a positive signalling event to occur using survival modelling by incorporating a 114 
hazard sub-model. Finally, a novel feature of this work is the addition of an additional sub-115 
model to account for contaminated TTP samples, implemented as a probability component to 116 
describe differences in the probability of TTP contamination over time and between the 117 
different study sites.  118 
 119 
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 120 
Modelling of MBL data 121 
The MBL data was described through a sputum sub-model describing the total bacterial load 122 
in the patient’s sputum. The sputum model that was used as a starting point included a single 123 
mycobacterial subpopulation with exponential kill where bacterial load in sputum (Bs) over 124 
time on treatment (tt) was calculated according to: 125 
𝐵𝑠(𝑡𝑡) = 𝐵0,𝑠 × 𝑒
−𝑘×𝑡𝑡 (Eq. 1) 126 
where the MBL prediction was set equal to the bacterial load (i.e. MBL(tt)=Bs(tt)). The B0,s 127 
parameter describes the initial (pre-treatment) bacterial load and k is a first-order kill rate 128 
exhibited by the combination treatment. In this way, the drug effect was modelled as an 129 
“on/off” treatment effect  not accounting for drug concentrations, i.e. this concentration-130 
independent approach ignores pharmacokinetics. As this work developed, we tested a model 131 
that included two mycobacterial subpopulations (B1s and B2s, respectively) with first-order 132 
rate constants for bacterial killing (k1 and k2, respectively) according to:  133 
𝐵𝑠(𝑡𝑡) = 𝐵10,𝑠 × 𝑒
−𝑘1×𝑡𝑡 + 𝐵20,𝑠 × 𝑒
−𝑘2×𝑡𝑡 (Eq. 2) 134 
where B10,s and B20,s describe the initial bacterial load of B1 and B2, respectively. In addition 135 
to the two subpopulation model, a three subpopulation was also tested. As a molecular 136 
measure we assumed that MBL captured a total population and, thus, the prediction of MBL 137 
was set to the sum of the different bacterial subpopulations in sputum. The MBL data that 138 
were below the LLOQ which was set to 100 CFU/mL in this work was handled using the M3 139 
method within NONMEM which is a preferred way for missing data (13). 140 
 141 
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 142 
Modelling of MBL-TTP data  143 
For modelling TTP, the sputum sub-model established based on the MBL data was extended 144 
with additional sub-models (a schematic representation of how the different sub-models 145 
connect can be seen in Figure 1). Thus, the sputum sub-model had a central role within the 146 
model, and acted as the main driver for time-varying changes in both biomarkers.   The 147 
starting point for model development of TTP-related sub-models was derived from a previous 148 
TTP model (8). A mycobacterial growth component described bacterial growth in the liquid 149 
culture. The starting point for bacterial growth (the inoculum) for each liquid culture sample 150 
was the predicted bacterial load at the corresponding time-point from the sputum sub-model 151 
according to: 152 
𝐵𝑠(𝑡𝑡 = 𝑡𝑠𝑎𝑚𝑝𝑙𝑒) → 𝐵𝑐(𝑡𝑐 = 0) (Eq. 3) 153 
where tsample is the time-point of sampling (relative to start of treatment) and Bc is the bacterial 154 
density in liquid culture and tc is time since liquid culture inoculation. In general for 155 
equations, tt (time since start of treatment) signifies processes in the patient (e.g. bacterial 156 
killing) whereas tc (time since MGIT incolulation) mainly concerns processes within the 157 
liquid culture. The existence of more than one mycobacterial subpopulation that we explored 158 
for the sputum model (e.g. in Equation 2) was considered for the mycobacterial growth model 159 
also in which the starting point for bacterial growth was described by Equations 4 and 5.  160 
𝐵1𝑠(𝑡𝑡 = 𝑡𝑠𝑎𝑚𝑝𝑙𝑒) → 𝐵1𝑐(𝑡𝑐 = 0) (Eq. 4) 161 
𝐵2𝑠(𝑡𝑡 = 𝑡𝑠𝑎𝑚𝑝𝑙𝑒) → 𝐵2𝑐(𝑡𝑐 = 0) (Eq. 5) 162 
Upon exploring the existence of more than one subpopulation in the liquid culture, potential 163 
qualitative differences between subpopulations were tested including different growth rates 164 
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for the subpopulations and a transfer between subpopulations. Models were also tested 165 
including the existence of a non-growing subpopulation (alongside a growing population) to 166 
explore if this could explain an expected time-varying change in the MBL vs TTP relationship 167 
(similar hypotheses exists for the CFU vs TTP relationship) (14). Exponential, logistic and 168 
Gompertz growth functions were tested. 169 
The mycobacterial growth model was coupled to a hazard model to translate growth in the 170 
MGIT liquid culture to a probability of a positive TTP signal.  171 
Bacterial population density inside the liquid culture was the assumed contributor to the 172 
probability of a positive TTP signal. Bacterial population was an assumed proxy for carbon 173 
dioxide production, the known driver for a positive TTP signal (in this bacteria were assumed 174 
to be growing and this carbon dioxide producing). Note that no formal distinction was made 175 
between bacterial growth and carbon dioxide production which means that the bacterial 176 
grwoth represent a combination of carbon dioxide production and bacterial growth. A scaling-177 
parameter controlled how much each bacterium inside the liquid culture contributed to the 178 
probability of a positive signal, as seen in Equation 6.  179 
ℎ(𝑡𝑐) = 𝐵𝑐(𝑡𝑐) × 𝑆𝑐𝑎𝑙𝑒 (Eq. 6) 180 
where h is the hazard and described the instantaneous probability for a positive signalling 181 
event and Scale is a scaling-parameter controlling each bacterium’s contribution to the hazard. 182 
Next, the integral of the hazard over time (H) were calculated using Equation 7. 183 
𝐻(𝑡𝑐) = ∫ ℎ(𝑡𝑐)𝑑𝑡
𝑡𝑐
0
) (Eq. 7) 184 
The survival (S, the probability over time to remain free of a positive signalling event) was 185 
calculated by Equation 8. 186 
𝑆(𝑡𝑐) = 𝑒
−𝐻(𝑡𝑐)  187 
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For mycobacterial growth models including more than one mycobacterial subpopulation, we 188 
tested for differences in the degree of contribution to the probability of a positive TTP signal 189 
for each subpopulation.   190 
Developing our work further, a component for the probability of contaminated TTP samples 191 
was developed. Tested models included constant (Equation 9) and linearly increasing 192 
probabilities (Equation 10) of contamination over time on treatment.  193 
𝑝𝑐𝑜𝑛𝑡𝑎𝑚𝑖𝑛𝑎𝑡𝑒𝑑,𝑇𝑇𝑃 = 𝑝𝑐𝑜𝑛,𝑏𝑎𝑠𝑒 (Eq. 9) 194 
𝑝𝑐𝑜𝑛𝑡𝑎𝑚𝑖𝑛𝑎𝑡𝑒𝑑,𝑇𝑇𝑃 = 𝑝𝑐𝑜𝑛,𝑏𝑎𝑠𝑒 + 𝑘𝑝 × 𝑡𝑡 (Eq. 10) 195 
where pcontaminated,TTP is the probability of a contaminated TTP sample, pcon,base is the baseline 196 
probability of a contaminated TTP sample and kp is a linear time-varying increase of 197 
probability of a contaminated TTP sample. Since the sputum sampling and testing for 198 
contamination differed between the sites, models were tested where separate contamination-199 
related parameters were estimated for each site.  200 
At the beginning of model development, negative TTP samples were handled within the time-201 
to-event approach using right-censoring (the standard procedure for survival modelling). This 202 
was compared to a model where negative samples were handled by treating negative TTP 203 
samples as a different type of data observation in a separate sub-model (10). The probability 204 
of a negative TTP sample was described by an Emax relationship between bacterial load in 205 
sputum and the probability of a negative TTP (pnegative,TTP) according to Equation 11 206 
(exemplified for a two subpopulation sputum model). 207 
𝑝𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒,𝑇𝑇𝑃 = 1 −
𝑝𝑚𝑎𝑥×(𝐵1𝑠(𝑡𝑡)+𝐵2𝑠(𝑡𝑡))
𝛾
𝐵50
𝛾
+(𝐵1𝑠(𝑡𝑡)+𝐵2𝑠(𝑡𝑡))
𝛾  (Eq. 11) 208 
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where pmax is the maximal probability of a positive TTP sample, B50 is the bacterial load of 209 
subpopulation 1 and subpopulation 2 in sputum at which the probability of a positive TTP 210 
value is half maximal and γ is a gamma-factor for the shape of the non-linear relationship. 211 
 212 
Covariate model 213 
Rifampicin dose group of 35- versus 10- mg/kg was tested as a covariate on the bacterial kill 214 
rate in the sputum sub-model as well as HIV status on baseline bacterial load. Another 215 
potential covariate to evaluate would be to test if pooled versus early morning sputum 216 
samples gave different baseline bacterial load (pooled samples are known to have shorter 217 
TTP) but this was note tested in this analysis. The reasons were that a graphical exploration of 218 
the data revealed no apparent differences between baseline TTP for pooled versus early 219 
morning samples and that all samples from each site had the same sampling. This would in 220 
turn have made it difficult to separate this effect between sampling method and site or region.  221 
Another relevant covariate would have been lung cavitation on baseline bacterial load but this 222 
information was unavailable in the current dataset. 223 
 224 
 225 
Utility of the model 226 
The intended real-life use of the model was evaluated by re-estimating the final combined 227 
MBL-TTP model by only using the MBL or TTP data, respectively, to explore if the final 228 
combined model can be applied to predict TTP from MBL data and vice versa, in trials where 229 
only MBL or TTP are collected. Note that this was an actual re-estimation (i.e. not 230 
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MAXEVAL=0) but parameters strongly associated with the biomarker left out of the 231 
estimation were fixed to that of the combined MBL-TTP model. Furthermore, the model re-232 
estimated with TTP only data can potentially be used as a standalone TTP model to analyse 233 
future TTP only datasets (but note that this work does not include validation for prospective 234 
use per se). In this situation, the MBL sub-model parameters were fixed to the estimates from 235 
the combined model when estimating only TTP data and vice versa. The evaluation was based 236 
on graphical diagnostic plots, plausibility of parameter estimates and uncertainty in parameter 237 
estimates.  238 
 239 
Data analysis and model evaluations 240 
The data were analysed in NONMEM 7.4 with the importance sampling (IMP) estimation 241 
method. The Laplacian estimation method did not give stable estimation for analysing MBL 242 
and TTP simultaneously. Detailed estimation settings are listed in Supplementary data S1. 243 
Data handling and plotting were done in R 3.5.1 using Xpose 4.6.1 (15) to make diagnostic 244 
plots assisted by PsN 4.8.0 (16). Models were compared based on difference in objective 245 
function value (dOFV) using the likelihood ratio test at the 1% significance level but also 246 
based on uncertainty in model parameters. 247 
Models were assessed graphically using visual predictive checks (VPCs). For MBL, 248 
conventional VPCs were generated which compared percentiles of observed and simulated 249 
data within the same plot. If the observed and simulated data agreed, it provided evidence that 250 
the model provided a good description of the observed data.  251 
For TTP (time-to-event data), Kaplan-Meier VPCs (see e.g. (17)) were produced, which 252 
compared observed and simulated Kaplan-Meier curves for TTP at each week. Finally, VPCs 253 
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were performed for TTP versus MBL to assess if the model could mimic the observed pattern 254 
(relationship) between the biomarkers.  255 
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Results 256 
Patient data 257 
Patient baseline characteristics are summarized in Table 1. For MBL, 851 samples were 258 
analysed of which 277 samples (32.5%) were below the employed LLOQ of 100 CFU/mL. 259 
For TTP, 659 samples were analysed of which 192 samples (29.1%) were contaminated and 260 
90 samples (13.7%) were negative (i.e. the TTP was greater than 42 days). 261 
 262 
Sub-model for MBL data 263 
The developed sputum model included two mycobacterial subpopulations, B1 and B2 where 264 
the treatment had exponential killing of both subpopulations where the MBL prediction was 265 
assumed to represent the total bacterial population (i.e. MBL(tt)=B1s(tt)+B2s(tt)). The B1 266 
subpopulation had greater abundancy (~99%) than B2 (~1%) at pre-treatment and the B1 267 
subpopulation was also more easily killed than B2 (B1 killed ~3.5 times more rapidly than 268 
B2). Thus, B2 were more tolerant to treatment-induced bacterial killing which led to that B2 269 
becoming more abundant than B1 during late treatment. A statistically significant increased 270 
kill (1.66 fold) of B1 (but not B2) by rifampicin 35 vs 10 mg/kg (p=0.002) was included in 271 
the model. The HIV covariate on initial bacterial load was not statistically significant. The 272 
MBL model gave good description of the observed data according to a VPC (Figure S1). 273 
Inclusion of two mycobacterial subpopulations in the sputum model gave a significantly 274 
better fit to the observed data than a sputum model only including a single subpopulation 275 
(p<0.00001). The treatment had first-order killing of both subpopulations (included as an 276 
“on/off” treatment effect). In the final MBL sputum sub-model bacteria were assumed to be 277 
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unable to grow or transfer between subpopulations in sputum. A three subpopulation model 278 
was not supported by the data as it resulted in an unstable estimation. 279 
Inclusion of inter-individual variability in initial bacterial load of both subpopulations (B1 and 280 
B2), also including a correlation between the subpopulations led to a significantly better fit to 281 
the observed data and was therefore included in the final model.  282 
The final model for MBL with an intended use of modelling future MBL only datasets, 283 
referred to as the standalone MBL model is given in Supplementary data S2. Parameter 284 
estimates are shown in Supplementary data S3.  285 
 286 
Combined MBL-TTP model 287 
The structure of the final combined MBL-TTP model is shown in Figure 1. The dynamics of 288 
each sub-model are shown for baseline and week 12 samples in addition to week 4 (which 289 
was considered relevant since it’s located in the transition between the initial rapid decline 290 
and the later slower decline for bacterial load in sputum) for a typical individual in Figure 2. 291 
The final combined MBL-TTP model included the same sputum model as described above for 292 
the standalone MBL model. The same subpopulations as described within the sputum model 293 
existed within the mycobacterial growth model where only the B1 population could grow. 294 
However, B2 bacteria were able to transfer into B1 in the liquid culture (Figure 1). The model 295 
component for contaminated TTP samples included a linear relationship between time on 296 
treatment and risk of contamination. Finally, the model included a component for negative 297 
TTP including a non-linear (Emax) relationship between bacterial load in sputum and 298 
probability of negative TTP. Figure 3 compares sample loss due to negative and/or 299 
contaminated samples for TTP vs MBL. The figure shows that both MBL and TTP have 300 
similar degree of negative samples (Figure 3a) but due to the much higher contamination of 301 
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TTP (Figure 3b), the MBL assay gives more information in terms of non-contaminated, 302 
positive samples (Figure 3c). 303 
Simulated data from the final combined MBL-TTP model gave good description of the 304 
observed data which showed that the model was appropriate given the data. A plot of 305 
observed and model-predicted TTP vs MBL shows that the final model accurately described 306 
the observed pattern between the biomarkers (Figure 4). A VPC of MBL vs time (Figure 5) 307 
and a Kaplan-Meier VPC of TTP vs time in liquid culture for different treatment weeks 308 
(Figure 6) also showed that the model described the observed data well. Parameter estimates 309 
of the final combined MBL-TTP model are shown in Table 2. Precision looked fine for all 310 
parameters. All parameters were estimated on linear scale. 311 
For the mycobacterial growth model only B1 could grow but B2 could transfer into B1. A 312 
transfer rate parameter (k21) described the transfer between B2 and B1 and was set to the same 313 
value as the growth rate (kG). Estimation of a unique k21 led to an unstable model and was not 314 
statistically significant (p=0.176). The growth function that best described the growth of B1 315 
was found to be the Gompertz model.  316 
Bacterial growth was linked to the probability of a positive TTP signal using a time-to-event 317 
approach where only B1 contributed to the probability (hazard) of a positive signal (since B2 318 
was non-growing B2 do not contribute directly to hazard). The contribution of each B1 319 
bacterium to the probability of a positive signal was determined by a scaling-parameter. The 320 
scaling-parameter was time-varying in the final model where the value decreased 321 
exponentially from a baseline value down to a steady state value. Having a similar time-322 
varying component for other potentially relevant parameters, such as the growth rate (kG) or 323 
introducing a lag-time for growth, did not lead to a stable model. 324 
 o
n
 August 8, 2019 at ST ANDREW
S UNIV
http://aac.asm
.org/
D
ow
nloaded from
 
17 
 
The model for contaminated samples was different between sites. However, parameters 325 
estimated from the Tanzania site were considered the most appropriate model. For Tanzania, 326 
the observed contamination rate was low initially (~10%) and increased linearly to reach a 327 
contamination rate of ~60% by week 12. For Malawi, contamination was not determined (i.e. 328 
no blood agar test was done). For Mozambique, contamination was moderately high (~30-329 
40%) across all time-points. A VPC for contamination vs time (Figure S2) confirmed that the 330 
model gave a good description of the observed contamination data. 331 
A sub-model was included in the final model to handle negative TTP. The probability of a 332 
negative sample increased as bacterial load in sputum decreased (10). An inhibitory sigmoidal 333 
Emax-model described the relationship where the lowest possible probability of a negative 334 
sample was estimated to be 3.3% and occurred at a very high bacterial density. The 335 
probability of a negative sample was half-maximal at a bacterial density of 48.8 CFU/mL. 336 
This is a rather low number which represents roughly half the LLOQ of 100 CFU/mL which 337 
was used in this analysis for MBL. A model where negative TTP samples were handled using 338 
right-censoring within the hazard model (which is common practice for time-to-event models) 339 
did not lead to an acceptable description of the observed data and was therefore discarded. 340 
Inter-individual variability was included for the scaling-parameter that accounted for the 341 
contribution of B1 to the probability of a positive signalling event in the liquid culture. 342 
 343 
Utility of the final model 344 
It was possible to re-estimate the final combined MBL-TTP model using only MBL data if the 345 
TTP-related parameters were fixed to the parameters of the final model, where the model gave 346 
good description of the observed MBL data (Figure S3). The final model with the TTP-related 347 
parameters fixed can be found in Supplementary data S2.  Likewise, we successfully re-348 
 o
n
 August 8, 2019 at ST ANDREW
S UNIV
http://aac.asm
.org/
D
ow
nloaded from
 
18 
 
estimated the final model with only TTP data with MBL-related parameters fixed to the final 349 
model estimates with good fit to the observed data (Figure S4). The model estimated with 350 
TTP only data can be used as a standalone TTP model to estimate TTP only datasets. The 351 
final MBL-TTP model with the MBL-related parameters fixed can be found in Supplementary 352 
data S2. 353 
A comparison of parameter estimates for the final combined MBL-TTP model estimated 354 
including all data, the final model re-estimated with MBL or TTP data only and the 355 
standalone MBL model can be found in Supplementary data S3. There was consistency in the 356 
estimated parameters between all the models. The covariate effect of enhanced performance 357 
of 35 mg/kg rifampicin was estimable using all models, i.e. using MBL or TTP data only as 358 
well as with all data.   359 
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Discussion 360 
This analysis describes the development of a pharmacometric model to identify the 361 
relationship between two critical measures of viable count; MBL and TTP based on data 362 
collected during 12 weeks in drug-susceptible TB patients treated with the standard drug 363 
combination. In this model the relationship between the biomarkers was identified 364 
successfully.  365 
To make an effective model it was necessary to include components that described the 366 
different data types; MBL is a continuous variable whereas TTP is a time-to-event variable 367 
indirectly reflecting bacterial load. The best sputum model (describing the underlying 368 
bacterial load in sputum) was achieved when we included two mycobacterial subpopulations 369 
(B1 and B2) with treatment resulting in an exponential fall in viable count for both. The 370 
predicted MBL was assumed to be the total bacterial population in sputum (i.e. 371 
MBL(tt)=B1s(tt)+B2s(tt)). Although the drug effect was included as an “on/off” treatment 372 
effect which represents a limitation of the present study, in the future it can/will be replaced 373 
by exposure-response relationships in later analyses. In our model the B1 subpopulation was 374 
more abundant than B2 at pre-treatment whereas B2 became more abundant than B1 on late 375 
treatment days since B1 was killed more rapidly than B2. This is similar to the report of 376 
Honeyborne et al. (5) although their work only included MBL data. We agree with their 377 
analysis that the  B2 population may represent persisters (5). A three subpopulation model 378 
was tested during the model development. A three subpopulation model reflective of 379 
multiplying, semi-dormant and persister cells would have been a more mechanistically 380 
plausible structure compared to the two subpopulations described in this work as TB is known 381 
to exist in at least three subpopulations (18). To interpret these results we may need to 382 
consider that the B1 and B2 subpopulations may also partly contain semi-dormant cells 383 
although to what extent this occurs is unknown. This also had implications when exploring 384 
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the relationship between MBL and TTP; with only two subpopulations included we were not 385 
able to appropriately explore our hypothesis that MBL reflects more bacterial subpopulations 386 
than TTP (i.e. we could not explore if TTP quantified semi-dormant but not persister cells 387 
without semi-dormant cells in the model). According to the final model structure both 388 
subpopulations contributed to MBL and TTP which can be interpreted as that both biomarkers 389 
reflect the same subpopulations. However, we do not have this view of our results, we still 390 
hypothesize that MBL may reflect more subpopulations than TTP and that our results just 391 
confirm that there is a large overlap in what subpopulations each biomarker captures. Yet we 392 
found that the three subpopulation model was not stable although the reasons for this are 393 
unknown. 394 
However, one potential explanation to the instability is that the clinical data used for this 395 
analysis contained a sub-optimal number of “critical” data points where persisters are 396 
expected to be the dominating subpopulation which we believe occur primarily at late time-397 
points (Figure 3). If a lower MBL LLOQ than 100 CFU/mL is applied in a future analysis it 398 
may lead to more critical data points. Another option where critical persister-dominated data 399 
points can be studied in controlled settings could be in vitro systems. Alternatively, the MBL 400 
information can be supplemented with information from staining-based techniques to identify 401 
phenotypic resistance based on lipid bodies (19), a study that is currently underway. 402 
An important advance in this model is the way in which it includes a sub-model that allowed 403 
us to predict TTP in a mechanistically plausible manner (Figure 1). The sputum model acted 404 
as the fundamental hub within the model where changes in the predicted bacterial load in 405 
sputum affected both the resulting MBL and TTP predictions. As anticipated, the relationship 406 
between MBL and TTP lies in the sputum model. The most essential way that the sputum 407 
model affected the TTP predictions was through the mycobacterial growth model describing 408 
growth in liquid culture as well as the hazard model which described how growth affected the 409 
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probability of a positive signal. This way of linking sub-models has been described in other 410 
time-to-event models only describing TTP data (8–10). Although the general structure of our 411 
model is similar to previous reports, what makes our model unique is the description of two 412 
distinct bacterial subpopulations both in the sputum model and in the mycobacterial growth 413 
model. The underlying study had no experimental data which could distinguish between the 414 
two populations, this was instead described by the mathematical model. In the liquid culture, 415 
B2 was non-growing but could indirectly contribute to growth by transferring into B1 416 
potentially reflecting a shift to a more metabolically active state triggered by the nutrient-rich 417 
liquid culture media. The transfer rate of B1 transferring to B2 (k21) was set to the same value 418 
as the bacterial growth rate (kG). This was reasonable given the insufficient data to inform 419 
differences in these parameters. Furthermore, when the mycobacterial growth model was 420 
linked to the hazard model which translates the growth in the liquid culture to a probability of 421 
a positive signal, only B1 contributed to the probability of a positive TTP. As the underlying 422 
reason for a positive signalling is carbon dioxide production this implies that non-growing B2 423 
bacteria do not contribute measurably to carbon dioxide production. Both findings, i.e. that B2 424 
is non-growing and do not produce carbon dioxide were driven by the data and are important 425 
observations. It may explain a disproportionally greater TTP prolongation on early versus late 426 
treatment days as not only the MGIT inoculum decrease each week, the proportion of bacteria 427 
that can grow and readily produce carbon dioxide immediately upon liquid culture inoculation 428 
has also decreased (i.e. the B1/B2 ratio decrease with treatment time). This observation agrees 429 
with and provide further insight into a hypothesis generated in a non-model-based analysis 430 
comparing CFU, time to appearance of CFU and TTP (20).  In that study (20) there was 431 
significant correlation between time to appearance of the first CFU colony on solid media and 432 
TTP suggesting that the fastest growing bacteria has a disproportionally larger contribution to 433 
the carbon dioxide production in liquid culture, i.e. a similar interpretation as can be drawn 434 
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from our work. Another finding within our model that also contributes to this relationship is 435 
the time-varying scaling-parameter which decreased with time on treatment. The time-varying 436 
scaling parameter is, once again, a data-driven finding. Future in vitro work should explore 437 
the biological explanation.  438 
Previous models have treated TTP as a continuous variable (21–24). Our work suggests that 439 
this is not the optimal way to handle these data as time-to-positivity reflects time-to-event 440 
data. As was the case for a previous publication, a time-to-event analysis of TTP revealed an 441 
exposure-response relationship of rifampicin (8) that was undetected for the same dataset 442 
when the TTP data was treated as continuous data (25).  443 
One of the challenges of modelling data from TB clinical trials is that previously published 444 
MGIT-TTP models lack components for contamination, which is a significant confounder of 445 
this assay. Thus, the contamination sub-model is a significant improvement on the previously 446 
published models for TTP since it allows for real-world clinical trial simulations. Our model 447 
can be used to make simulations prior to performing clinical TTP studies to predict the degree 448 
of TTP sample loss. We regard the predicted and observed degrees of contamination as high 449 
(Figure 3) suggesting that TTP can be unreliable and difficult to interpret, especially during 450 
late treatment thus, making it meaningful to get a reliable expectation on the degree of sample 451 
loss. Significantly, it means that MBL, which is not affected by contamination is a significant 452 
improvement over TTP as shown in Figure 3. The typical patient is expected to have greater 453 
sample loss for TTP than MBL when accounting for both contamination and negative 454 
samples. The included component for contaminated TTP was based on time on treatment and 455 
was site-dependent but we recommend the contamination model derived from Tanzania for 456 
performing clinical trial simulations since contamination for Tanzania data started low at 457 
baseline and increased with time on treatment, which represents the most plausible 458 
contamination pattern. It has been shown that during early treatment patients produce sputum 459 
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of better quality than later on treatment where patients get healthier which is associated with a 460 
relative inability to produce sputum (26).   461 
A sub-model was included to describe negative TTP samples which predicted that lower 462 
bacterial densities in sputum gave higher probability of a negative TTP sample. This way of 463 
handling negative TTP samples is similar as a previous model for TTP (10). An Emax model 464 
described this relationship (Figure 2e) and predicted a probability of a negative TTP of 3.3% 465 
at very high bacterial densities suggesting that a fraction of TTP samples will always be 466 
negative. The model by Svensson and Karlsson (10) predicted that 3.1% will always be 467 
negative which is similar to our value. 468 
The developed model gave good fit to the observed data according to the diagnostic plots in 469 
Figures 4-6. In addition, the parameter precision in the parameters was overall low (Table 2). 470 
This shows that from a technical model validation perspective, the presented model is valid. 471 
In this work we identified a statistically significant increased (1.66 fold) killing effect for 35 472 
vs 10 mg/kg rifampicin which indicates that the joint collection of MBL and TTP data used 473 
along with our modelling approach is a powerful strategy for detecting inter-regimen 474 
differences for Phase IIb trials. If studies are designed and analysed according to our approach 475 
Phase IIb trial performance may be simplified and could require fewer patients to be recruited. 476 
However, this was based on data from 12 patients and the model as such was not tested on 477 
any external data. 478 
The utility analysis showed that the model can be used to analyse MBL data alone to predict 479 
TTP and vice versa if parameters related to the excluded biomarker are fixed according to 480 
Supplementary data S3. We argue that using the model in this way should be valid for data 481 
from drug-susceptible TB patients. However, for drug-resistant TB the bacterial killing may 482 
be slower and initial bacterial load as well as growth rate in liquid culture may deviate and 483 
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studies investigating this are required. One of the most encouraging aspects of this model is 484 
that the parameter for difference in bacterial kill for 35 vs 10 mg/kg rifampicin was 485 
identifiable when using data from one or the other biomarker or when using data from both.  486 
The original study (11) which reports the underlying data had not gone through formal peer-487 
review by the time of manuscript submission of the present work. 488 
The developed pharmacometric model predicted a general trend of lower probability of TTP 489 
culture conversion at week 8 for higher bacterial loads compared to lower bacterial loads. 490 
This conclusion could probably not have been drawn as easily directly from the observed 491 
data. In the observed data the mean baseline TTP was 5.7 days for patients with culture 492 
negativity at week 8 and the mean baseline TTP was 6.0 for patients with culture positivity at 493 
week 8. For other time-points (including weeks 1, 4 and 6), the mean TTP was also similar 494 
between patients with and without culture conversion at week 8. However, for week 2 there 495 
mean TTP was higher for patients with culture negativity at week 8 (15.6 days) compared to 496 
patients with culture positivity at week 8 (9.8 days). 497 
In conclusion, our work reports a practical combined MBL-TTP model that relates the 498 
changing bacterial load for both markers. We also developed two sub-models that can be used 499 
to analyse TTP and MBL separately. The combined MBL-TTP model can be used to predict 500 
TTP from MBL data and vice versa and could be used to re-analyse historical trials. We 501 
confirm and delineate the extent that MBL gives higher proportion of positive samples than 502 
TTP due to high proportion of contaminated TTP samples. The standalone MBL model can be 503 
used to analyse clinical trials where exposure-response of drugs and regimens quantified with 504 
only MBL is of interest.   505 
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Figures legends 613 
Figure 1 Schematic representation of the final combined MBL-TTP model. The treatment is 614 
represented by an “on/off” effect i.e. the drugs kill the bacteria in the presence of drugs. The 615 
killing of bacteria, represented by two mycobacterial sub-populations in the sputum (B1s and 616 
B2s) is governed by two first-order kill-rates (k1 and k2) in the sputum model. The sum of B1s 617 
and B2s constitutes the MBL sub-model and gives the prediction of MBL (MBL model, 618 
lowest middle box). The predicted bacterial densities of the sub-populations in sputum (B1s 619 
and B2s) are the inoculum for the mycobacterial growth model (top middle box), at the 620 
corresponding sampling time point. Only B1c in the liquid culture has the ability to grow. The 621 
B2c cannot grow but can transfer into the B1c subpopulation with a first-order rate of k21. A 622 
TTP model (top right box) translates the growth within the mycobacterial growth model to a 623 
positive TTP signal where only B1c contributes to the probability of a positive TTP signal. 624 
This is done using survival modelling, where B1c multiplied by a time-varying factor accounts 625 
for the relative contribution of each B1c bacterial cell to the probability of a positive signal. 626 
Negative TTP samples are described by a non-linear (Emax) relationship between the bacterial 627 
density in sputum (B1s+B2s) and probability of a negative TTP sample (upper middle box). 628 
Contaminated TTP samples are described by a function for the probability of a contaminated 629 
sample that increase linearly with time on treatment (lower middle box). 630 
Abbreviations: k1; first-order bacterial kill rate of bacterial sub-population B1s, k2; first-order 631 
bacterial kill rate of bacterial sub-population B2s , MBL; molecular bacterial load, TTP; time-632 
to-positivity,  633 
 634 
Figure 2 Typical model predictions within each component of the final combined MBL-TTP 635 
model for a patient treated with isoniazid, pyrazinamide, ethambutol and 10 mg/kg rifampicin. 636 
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The (a) panel shows predictions from the sputum model where the line represents the 637 
prediction of MBL. The (b) panel shows predictions of the bacterial density in the liquid 638 
culture. Remaining panels show the predicted time-varying probability of not having a 639 
positive TTP signal (c), probability of contaminated TTP samples (d) and probability of 640 
negative TTP samples (e). The different symbols in panels (a), (d) and (e) show the dynamics 641 
within the corresponding sub-model where circles represent an early baseline sample, squares 642 
represent an intermediate (4-week) sample and triangles represent a late (week 12) sample. In 643 
panels (b) and (c), the circles represent an early (baseline) sample, the squares represent an 644 
intermediate (4-week) sample and the triangles represent a late (week 12) sample. 645 
Abbreviations: MBL; molecular bacterial load, TTP; time-to-positivity 646 
 647 
Figure 3 Sample loss for MBL (filled circles) and TTP (filled triangles) due to (a) negative 648 
samples, i.e. assuming no loss of samples due to contamination, (b) contaminated samples, 649 
assuming no loss of samples due to negativity and (c) total sample loss reflecting the 650 
combined sample loss due to negative samples and contaminated samples. 651 
Abbreviations:  TTP; time-to-positivity, MBL; molecular bacterial load 652 
 653 
Figure 4 The relationship between TTP and MBL. The VPC shows the median (solid line) 654 
and 5
th
 and 95
th
 percentiles (lower and upper dashed lines, respectively) of observed data 655 
compared to the corresponding percentiles of simulated data (shaded areas) based on 1000 656 
simulated datasets where lighter grey are percentiles and darker grey is median. The open 657 
circles show the actual observations. 658 
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Abbreviations: TTP; time-to-positivity, MBL; molecular bacterial load, VPC; visual 659 
predictive check 660 
Figure 5 Visual predictive check (VPC) for the MBL data using the final combined MBL-661 
TTP model. The VPC shows the median (solid line) and 5
th
 and 95
th
 percentiles (lower and 662 
upper dashed lines, respectively) of observed data compared to the corresponding percentiles 663 
of simulated data (shaded areas) where lighter grey are percentiles and darker grey is median. 664 
The open circles show the actual observations and the dotted line is the lower limit of 665 
quantification for MBL. The shaded areas represent 95% confidence interval of simulated 666 
data based on 1000 simulated datasets. 667 
Abbreviations: MBL; molecular bacterial load 668 
Figure 6 Kaplan-Meier visual predictive check (VPC) of the TTP data using the final 669 
combined MBL-TTP model. The VPC shows the observed Kaplan-Meier (survival) curve for 670 
each weeks’ TTP as solid lines and the simulated Kaplan-Meier 95% confidence intervals are 671 
shown as blue shaded areas (n=1000 simulated datasets). 672 
Abbreviations: TTP; time-to-positivity, MGIT; mycobacterial growth incubator tube  673 
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Tables 674 
Table 1 – Baseline patient characteristics for all data and by study site 675 
Parameter All sites 
(n=105) 
Malawi 
(n=20) 
Mozambique 
(n=53) 
Tanzania 
(n=32) 
Weight (kg) 54 (37-74) 55.8 (43-70) 54.0 (37-74) - 
Male sex (n) 77 (73%) 14 (70%) 35 (66%) 28 (88%) 
HIV positive (n) 45 (42.9%) 9 (45.0%) 36 (67.9%) 0 (0%) 
Rifampicin 10 mg/kg (n) 93 (89%) 20 (100%) 53 (100%) 20 (63%) 
Rifampicin 35 mg/kg (n) 12 (11%) 0 (0%) 0 (0%) 12 (38%) 
Baseline TTP (days) 4.22 (1.02-
23.1) 
6.02 (3.14-
16.10) 
4.13 (2.00-9.60) 3.21 (1.02-
23.1) 
Negative baseline TTP 
(n)
a
 
2 (1.90%) 0 (0%) 2 (3.77%) 0 (0%) 
Baseline MBL (log10 
CFU/mL) 
5.91 (2.62-
8.37) 
5.43 (3.61-
7.83) 
6.35 (2.62-8.28) 5.26 (3.04-
8.37) 
Negative baseline MBL 
(n)
b
 
1 (0.95%) 0 (0%) 1 (1.89%) 0 (0%) 
Data are median values (ranges) or no. (%) of patients. 676 
aDefined as a TTP longer than 42 days bDefined as a log10 MBL value below 2 677 
Abbreviations: TTP; time-to-positivity, MBL; molecular bacterial load 678 
 679 
  680 
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Table 2 – Parameter estimates of the final combined MBL-TTP model 681 
Parameter Description Estimate  
Sputum model 
B10,s (CFU/mL) Initial bacterial load of mycobacterial 
subpopulation 1 in sputum 
0.365×10
6
 (28.8) 
k1 (week
-1
) First-order bacterial kill rate of subpopulation 1 in 
sputum 
1.71 (8.70) 
B20,s (CFU/mL) Initial bacterial load of mycobacterial 
subpopulation 2 in sputum 
0.00430×10
6
 (51.4) 
k2 (week
-1
) First-order bacterial kill rate of subpopulation 2 in 
sputum 
0.494 (9.50) 
Dose35mg Fold increase in bacterial killing of k1 by 35 versus 
10 mg/kg rifampicin 
1.66 (14.0) 
IIV B10,s (%) Inter-individual variability in B10,s 239 (9.18) 
IIV B20,s (%) Inter-individual variability in B20,s 227 (10.9) 
Corr B10,s – 
B20,s (%) 
Correlation between B10,s and B20,s 45.4 (15.6) 
ε (%) Additive error on log scale for MBL data 79.7 (4.96) 
Mycobacterial growth model 
kG (day
-1
)
a
 Mycobacterial growth of subpopulation 1 in liquid 
culture 
0.395 (8.50) 
k21 (day
-1
)
a
 Transfer rate from subpopulation 2 to subpopulation 
1 in liquid culture 
0.395 (8.50) 
Bmax (CFU/mL) Maximal bacterial load in liquid culture  166×10
6
 (24) 
TTP model 
ScaleBL Baseline value of scaling parameter accounting for 
the contribution of subpopulation 1 bacteria to the 
probability of a positive TTP signal 
6.68×10
-9
 (31.6) 
IIV ScaleBL (%) Inter-individual variability in ScaleBL 80.6 (18.1) 
ScaleSS Steady state value of scaling parameter 0.601×10
-9
 (24.3) 
kS (week
-1
) First-order rate constant for time-varying change of 
the scaling parameter 
1.28 (25.1) 
Model for negative TTP samples 
pmax Maximal probability of a positive TTP sample 0.967 (1.50) 
B50 Bacterial load of subpopulation 1 and subpopulation 
2 in sputum at which the probability of a positive 
TTP value is half maximal 
49.8 (33.7) 
γ Gamma-factor for non-linear Emax relationship for 
negative TTP samples 
0.756 (18.9) 
Model for contaminated TTP samples 
pcon,base
c
 Baseline probability of a contaminated TTP sample 0.0910 (39.0) 
kp
c
 Linear time-varying increase of probability of a 
contaminated TTP sample 
0.0416 (13.9) 
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The reported values are the final estimates with relative standard error (RSE) shown in brackets as the 682 
approximate coefficient of variation (%CV) on standard deviation scale. The IIV and residual error are shown as 683 
the approximate %CV on standard deviation scale (calculated using a simple square-root formula, 684 
%CV=100×√(variance)). Correlation (Corr B10,s – B20,s) is reported as the percentage correlation coefficient. 685 
The mathematical structure for the final model was as follows (final NONMEM code in Supplementary data S2): 686 
𝐵1𝑠(𝑡𝑡) = 𝐵10,𝑠 × 𝑒
−𝑘1×𝑡𝑡×Dose35𝑚𝑔 (B1 subpopulation in sputum) 687 
𝐵2𝑠(𝑡𝑡) = 𝐵20,𝑠 × 𝑒
−𝑘2×𝑡𝑡 (B2 subpopulation in sputum) 688 
where Dose35mg is 0 for 10 mg/kg rifampicin and the individually predicted MBL=B1s(tt)+B2s(tt) 689 
𝑑𝐵1𝑐
𝑑𝑡𝑐
= 𝐵1𝑐(𝑡𝑐) × 𝑘𝐺 × log (
𝐵𝑚𝑎𝑥
𝐵1𝑐(𝑡𝑐)+𝐵2𝑐(𝑡𝑐)
) + 𝑘21 × 𝐵2𝑐(𝑡𝑐) (B1 subpopulation in liquid culture) 690 
𝑑𝐵2𝑐
𝑡𝑐
= −𝐵2𝑐(𝑡𝑐) (B2 subpopulation in liquid culture) 691 
where the initial conditions for each TTP sample were 𝐵1𝑐(𝑡𝑐 = 0) = 𝐵1𝑠(𝑡𝑡 = 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡) and 692 
𝐵2𝑐(𝑡𝑐 = 0) = 𝐵21𝑠(𝑡𝑡 = 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡) for the B1 and B2 subpopulations, respectively 693 
ℎ(𝑡𝑐) = 𝐵1𝑐(𝑡𝑐) × (𝑆𝑐𝑎𝑙𝑒𝐵𝐿 + (𝑆𝑐𝑎𝑙𝑒𝑆𝑆 − 𝑆𝑐𝑎𝑙𝑒𝐵𝐿) × (1 − 𝑒
−𝑘𝑆×𝑡𝑡)) (TTP model) 694 
where the cumulative hazard (𝐻(𝑡𝑐) = ∫ ℎ(𝑡𝑐)𝑑𝑡
𝑡𝑐
0
) were used to calculate the survival (𝑆(𝑡𝑐) = 𝑒
−𝐻(𝑡𝑐)) 695 
𝑝𝑐𝑜𝑛𝑡𝑎𝑚𝑖𝑛𝑎𝑡𝑒𝑑,𝑇𝑇𝑃 = 𝑝𝑐𝑜𝑛,𝑏𝑎𝑠𝑒 + 𝑘𝑐𝑜𝑛 × 𝑡𝑡 (model for contaminated TTP samples) 696 
𝑝𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒,𝑇𝑇𝑃 = 1 −
𝑝𝑚𝑎𝑥×(𝐵1𝑠(𝑡𝑡)+𝐵2𝑠(𝑡𝑡))
𝛾
𝐵50
𝛾
+(𝐵1𝑠(𝑡𝑡)+𝐵2𝑠(𝑡𝑡))
𝛾  (model for negatvie TTP samples) 697 
*Final parameter estimates of the MBL standalone model, the model predicting TTP based on MBL and the 698 
model predicting MBL based on TTP are available in Supplementary data S3. 699 
ak21 and kG were modelled as a single parameter in the model, 
bThe parameters for contaminated TTP samples 700 
were estimated on data from Tanzania, the other sites included time-constant probabilities of 0 for Malawi (fixed 701 
value, since contamination was not measured) and 0.336 (10.0% RSE) for Mozambique 702 
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Abbreviations: TTP; time-to-positivity, tt; time on treatment, MBL; molecular bacterial load, tc; time in liquid 703 
culture, pcontaminated,TTP; probability for a contaminated TTP sample, pnegative,TTP; probability for a negative TTP 704 
sample 705 
 706 
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